Top-Rated Dividend StocksTop-Rated DividendNYSE:ABT Abbott Laboratories (ABT) Stock Price, News & Analysis $102.33 +0.30 (+0.29%) Closing price 03:59 PM EasternExtended Trading$102.78 +0.45 (+0.44%) As of 07:58 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsDividendEarningsFinancialsInsider TradesNews and TrendsOptions ChainOwnershipSEC FilingsShort Interest About Abbott Laboratories Stock (NYSE:ABT) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Abbott Laboratories alerts:Sign Up Key Stats Today's Range$101.50▼$103.3050-Day Range$88.96▼$116.7052-Week Range$81.97▼$137.49Volume5.23 million shsAverage Volume7.37 million shsMarket Capitalization$177.06 billionP/E Ratio33.12Dividend Yield2.46%Price Target$119.50Consensus RatingModerate Buy Company Overview Abbott Laboratories (NYSE: ABT) is a global healthcare company that develops, manufactures and sells medical products and technologies. Its operations span four principal areas: medical devices, diagnostics, established pharmaceutical products and nutrition. Abbott serves healthcare providers, institutions and consumers in markets around the world. The company’s medical device portfolio includes products for cardiovascular care, diabetes management and other specialties. Its diagnostics business provides laboratory systems, tests and point-of-care solutions, while its nutrition products include infant, child and adult nutritional offerings sold under brands such as Similac, Ensure and Pedialyte. Abbott also markets a broad range of branded generic pharmaceuticals in international markets. Founded in 1888 by Wallace C. Abbott, the company is headquartered in Abbott Park, Illinois, and has expanded from its origins as a pharmaceutical business into a diversified healthcare company. Abbott’s products are marketed in more than 160 countries. Robert B. Ford serves as the company’s chairman and chief executive officer.AI Generated. May Contain Errors. Read More Abbott Laboratories Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks97th Percentile Overall ScoreABT MarketRank™: Abbott Laboratories scored higher than 97% of companies evaluated by MarketBeat, and ranked 6th out of 903 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.8 / 5Analyst RatingModerate Buy Consensus RatingAbbott Laboratories has received a consensus rating of Moderate Buy. The company's average rating score is 2.96, and is based on 3 strong buy ratings, 20 buy ratings, 4 hold ratings, and no sell ratings.Upside PotentialAbbott Laboratories has a consensus price target of $119.50, representing about 16.8% upside from its current price of $102.33.Amount of Analyst CoverageAbbott Laboratories has been the subject of 11 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about Abbott Laboratories' stock forecast and price target. Earnings and Valuation2.5 / 5Proj. Earnings Growth10.14% Earnings GrowthEarnings for Abbott Laboratories are expected to grow by 10.14% in the coming year, from $5.52 to $6.08 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Abbott Laboratories is 33.12, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 38.87.Price to Earnings Ratio vs. SectorThe P/E ratio of Abbott Laboratories is 33.12, which means that it is trading at a less expensive P/E ratio than the Healthcare sector average P/E ratio of about 274.09.Price to Earnings Growth RatioAbbott Laboratories has a PEG Ratio of 1.91. PEG Ratios above 1 indicate that a company could be overvalued.Price to Book Value per Share RatioAbbott Laboratories has a P/B Ratio of 3.37. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Abbott Laboratories' valuation and earnings. Short Interest3.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted1.28% of the float of Abbott Laboratories has been sold short.Short Interest Ratio / Days to CoverAbbott Laboratories has a short interest ratio ("days to cover") of 2.67, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Abbott Laboratories has recently increased by 8.61%, indicating that investor sentiment is decreasing significantly. Dividend3.3 / 5Dividend StrengthStrong Dividend YieldAbbott Laboratories pays a meaningful dividend of 2.44%, higher than the bottom 25% of all stocks that pay dividends.Dividend GrowthAbbott Laboratories has been increasing its dividend for 54 years.Dividend CoverageThe dividend payout ratio of Abbott Laboratories is 81.55%. Payout ratios above 75% are not desirable because they may not be sustainable.Dividend SustainabilityBased on earnings estimates, Abbott Laboratories will have a dividend payout ratio of 41.45% next year. This indicates that Abbott Laboratories will be able to sustain or increase its dividend.Read more about Abbott Laboratories' dividend. News and Social Media4.4 / 5News Sentiment0.98 News SentimentAbbott Laboratories has a news sentiment score of 0.98. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.80 average news sentiment score of Healthcare companies.News Coverage This WeekMarketBeat has tracked 27 news articles for Abbott Laboratories this week, compared to 11 articles on an average week.Search Interest51 people have searched for ABT on MarketBeat in the last 30 days. This is an increase of 21% compared to the previous 30 days.MarketBeat Follows36 people have added Abbott Laboratories to their MarketBeat watchlist in the last 30 days. This is an increase of 157% compared to the previous 30 days. Company Ownership1.4 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, Abbott Laboratories insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $2,958.00 in company stock.Percentage Held by Insiders0.46% of the stock of Abbott Laboratories is held by insiders.Percentage Held by Institutions75.18% of the stock of Abbott Laboratories is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Abbott Laboratories' insider trading history. Receive ABT Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Abbott Laboratories and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. ABT Stock News HeadlinesIs Abbott (ABT) a Buy as Wall Street Analysts Look Optimistic?September 16 at 2:08 PM | finance.yahoo.comPoint of Care Diagnostics Market Forecasts Growth from $20.63B (2026) to $31.46B by 2031, Profiling QuidelOrtho, Sysmex, HemoCue, Trinity Biotech & 15 Other Key PlayersSeptember 16 at 9:07 AM | finance.yahoo.comIran War: Why Is Trump Protecting THEM?A powerful Middle Eastern government is reportedly seeking US intelligence, targeting help, and military protection against Iran-backed forces. An anonymous source says that protection was only one side of an extraordinary bargain, with the other side potentially worth trillions of dollars to America. Addison Wiggin traced the deal linking Trump, Iran, and this government, and says the headlines look very different once you know who is involved.September 16 at 1:00 AM | Banyan Hill Publishing (Ad)Abbott Laboratories (ABT) Agrees To $385 Million Infant Formula Recall SettlementSeptember 15 at 11:05 PM | finance.yahoo.comAbbott Reports First Commercial Use Of Volt Pulsed System In Canadian Atrial Fibrillation CareSeptember 15 at 6:04 PM | rttnews.comAbbott Faces $384 Million Cost as Infant Formula Legal Risks PersistSeptember 15 at 12:11 PM | insidermonkey.comAbbott To Pay $385 Mln To Resolve Claims Related To 2022 Infant Formula RecallSeptember 15 at 3:01 AM | rttnews.comModerna Just Doubled Overnight, and 2 More Healthcare Stocks Could Follow It (ABT)Moderna, Pharvaris and AbbVie span short, mid and long-term healthcare setups, from melanoma data to a Phase 3 catalyst and 13 straight years of dividend hikes.September 6, 2026 | marketbeat.comSee More Headlines ABT Stock Analysis - Frequently Asked Questions How have ABT shares performed this year? Abbott Laboratories' stock was trading at $125.30 on January 1st, 2026. Since then, ABT shares have decreased by 18.3% and is now trading at $102.3270. How were Abbott Laboratories' earnings last quarter? Abbott Laboratories (NYSE:ABT) posted its quarterly earnings data on Thursday, July, 16th. The healthcare product maker reported $1.31 EPS for the quarter, topping the consensus estimate of $1.28 by $0.03. The company's revenue for the quarter was up 13.0% compared to the same quarter last year. Read the conference call transcript. Does Abbott Laboratories have any subsidiaries? Abbott Laboratories subsidiaries include Cephea Valve Technologies, Alere, St. Jude Medical, Kalila Medical, Tendyne Holdings Inc., Veropharm, Topera Inc., and more. Who are Abbott Laboratories' major shareholders? Top institutional investors of Abbott Laboratories include BlackRock Inc. (8.82%), Bank of America Corp DE (1.02%), Deutsche Bank AG (0.97%) and Massachusetts Financial Services Co. MA (0.77%). Insiders that own company stock include Daniel J Starks, Robert B Ford, Jr Robert E Funck, Jr Robert E Funck, Daniel Gesua Sive Salvadori, Mary K Moreland, Andrea F Wainer, Lisa D Earnhardt, Eric Shroff, Elizabeth C Cushman, John A Jr Mccoy and Philip P Boudreau. View institutional ownership trends. How do I buy shares of Abbott Laboratories? Shares of ABT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Abbott Laboratories own? Based on aggregate information from My MarketBeat watchlists, some other companies that Abbott Laboratories investors own include JPMorgan Chase & Co. (JPM), Chevron (CVX), NVIDIA (NVDA), Predictive Oncology (POAI), Bank of America (BAC), Meta Platforms (META) and AbbVie (ABBV). Company Calendar Record date for 8/17 Dividend7/15/2026Ex-Dividend for 8/17 Dividend7/15/2026Last Earnings7/16/2026Dividend Payable8/17/2026Today9/16/2026Next Earnings (Estimated)10/21/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Yellow Zone (6d) 1-Year History Sep 25 Dec 25 Mar 26 Jun 26 Sep 26 For the last 6 days, ABT's financial health has been in the Yellow zone, according to TradeSmith. Industry, Sector and Symbol Stock ExchangeNYSE SectorHealthcare Industry Healthcare Equipment & Supplies Sub-IndustryHealthcare Equipment Current SymbolNYSE:ABT CIK1800 Webwww.abbott.com Phone(224) 667-6100Fax847-937-1511Employees115,000Year Founded1888Price Target and Rating Average Price Target for Abbott Laboratories$119.50 High Price Target$143.00 Low Price Target$92.00 Potential Upside/Downside+16.8%Consensus RatingModerate Buy Rating Score (0-4)2.96 Research Coverage27 Analysts Profitability EPS (Trailing Twelve Months)$3.09 Trailing P/E Ratio33.12 Forward P/E Ratio18.54 P/E Growth1.91Net Income$6.52 billion Net Margins11.65% Pretax Margin16.12% Return on Equity17.69% Return on Assets9.44% Debt Debt-to-Equity Ratio0.57 Current Ratio1.38 Quick Ratio0.97 Sales & Book Value Annual Sales$44.33 billion Price / Sales3.99 Cash Flow$6.94 per share Price / Cash Flow14.75 Book Value$30.35 per share Price / Book3.37Miscellaneous Outstanding Shares1,730,380,000Free Float1,722,423,000Market Cap$177.06 billion OptionableOptionable Beta0.59 Social Links 7 Stocks That Could Lead the Next Market BoomTesla, Nvidia, and Google helped shape the last era of market growth, but the next wave could come from a new group of companies. Inside this report, you’ll find 7 stocks that could play a major role in the next tech-driven market boom.Get This Free Report This page (NYSE:ABT) was last updated on 9/16/2026 by MarketBeat.com Staff. From Our PartnersA “bloodbath” Is ComingReports suggest some Silicon Valley billionaires are stockpiling gold, guns, and gas masks - or leaving the co...TradeSmith | SponsoredWhy major institutions are piling into this digital asset nowBlackRock, JPMorgan, Goldman Sachs, and Fidelity are reportedly accumulating a scarce blockchain asset - one t...Awesomely | SponsoredThe trade I’ve been waiting for since 2011Ross Givens, Director of Research at Traders Agency, is calling for gold to reach $10,000 an ounce this superc...Traders Agency | SponsoredTrump goes "all-in" on Grand Canyon energy breakthroughA drilling crew near the Grand Canyon uncovered a clean energy well producing nearly eight times the output of...Behind the Markets | SponsoredMILLIONAIRE MASTERCLASS INVITE: AltucherJames Altucher says Elon Musk is preparing an unprecedented project set to surface on September 25. Altuche...Paradigm Press | SponsoredGold majors have a big problemNewmont spent 15 billion dollars acquiring Newcrest in 2023, the largest deal in gold mining history. Yet prod...Golden Portfolio | SponsoredTrump's New DollarPorter Stansberry says President Trump has signed an executive order initiating what he calls a full U.S. doll...Porter & Company | SponsoredTSM just handed Trump's secretive AI project $100 billion — See this before September 29Taiwan Semiconductor just pledged another $100 billion to US chip manufacturing, bringing its total US investm...InvestorPlace | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Abbott Laboratories Please log in to your account or sign up in order to add this asset to your watchlist. Share Abbott Laboratories With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
